Bladder cancer is the ninth most common cancer worldwide, diagnosed in more than 614,000 patients each year globally. 1 MIBC represents approximately 30% of all bladder cancer cases. 2 The standard ...

Pfizer Inc. (NYSE:PFE) is one of the most buzzing stocks to invest in according to hedge funds. Earlier on December 17, ...

PADCEV plus KEYTRUDA is the first and only regimen to improve survival when used before and after standard of care (surgical cystectomy) in cisplatin-ineligible patients with muscle-invasive bladder ...

The combination of Keytruda and Padcev is taking another major step toward securing its position as a leading therapy in the treatment of bladder cancer. The PD-1/antibody-drug conjugate pairing ...

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive topline results from the Phase ...

Merck MRK announced that the FDA has approved both the intravenous (“IV”) and the subcutaneous (under the skin or SC) formulation of its blockbuster PD-L1 inhibitor, Keytruda (pembrolizumab), each in ...

Keytruda shows consistent efficacy and safety in advanced bladder carcinoma patients ineligible for platinum-based chemotherapy, with varying objective response rates and survival metrics across ...

The MarketWatch News Department was not involved in the creation of this content. -- PADCEV plus Keytruda is the first and only approved perioperative treatment regimen that can significantly improve ...

First and only systemic therapy to improve survival when used before and after surgery for patients with MIBC who are ineligible for cisplatin-based chemotherapy First ever positive Phase 3 study in ...

TOKYO and NEW YORK, Oct. 18, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Pfizer Inc. (NYSE: PFE) today announced positive results from the ...